Rethink and Pfizer Canada joint RFP

In 2021, Rethink Breast Cancer partnered with Pfizer Canada to launch a joint research program to fund pioneering research in metastatic breast cancer that has the potential to advance care and improve outcomes for people living with metastatic breast cancer. The areas of interest were determined by patients, for patients, through collaboration and input from Rethink’s MBC Advisory Board, and inspired by the James Lind Alliance‘s top 10 research priorities for MBC.

This collaboration brings patients’ voices and values to the process of supporting quality improvement initiatives to make a difference in the daily lives of people living with MBC. And this initiative has been made possible by the generous support of the Rethink community—especially MBC Allies—for our MBC Fund, by the passion and determination of our MBC Board, and by the openness of Pfizer Canada in collaborating to respond to the needs of those living with breast cancer.

We are so excited the joint RFP with Pfizer Canada is continuing in its fourth year in 2024!

Healthcare professionals from institutions across Canada are invited to apply to the joint 2024 Pfizer Canada / Rethink Breast Cancer RFP to help address the unmet needs of MBC patients.

Read more from MJ DeCoteau, Rethink’s Founder + Executive Director, on the collaboration and how it came to be, here.